Harrow Health Reports Q4 Earnings Miss with Strong Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy HROW?
Source: seekingalpha
- Earnings Performance: Harrow Health's Q4 GAAP EPS of $0.17 misses expectations by $0.20, indicating pressure on profitability that may affect investor confidence.
- Revenue Growth: The company reported Q4 revenue of $89.09 million, a 33.3% year-over-year increase, surpassing market expectations by $0.67 million, demonstrating strong demand and sales growth in the ophthalmic market.
- Future Outlook: Harrow Health's revenue guidance for full-year 2026 is set between $350 million and $365 million, with the first half projected at $133 million to $153 million and the second half at $203 million to $226 million, reflecting confidence in future growth.
- Adjusted EBITDA Guidance: The company anticipates adjusted EBITDA for 2026 to range from $80 million to $100 million, highlighting efforts to control costs and enhance profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HROW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HROW
Wall Street analysts forecast HROW stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 36.350
Low
63.00
Averages
72.40
High
94.00
Current: 36.350
Low
63.00
Averages
72.40
High
94.00
About HROW
Harrow, Inc. is a provider of ophthalmic disease management solutions. It offers a portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. Its product candidates include MELT-210, MELT-300 and MELT-400. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Harrow Inc. Reports Mixed Q4 Results with Earnings Miss
- Earnings Performance: Harrow Inc. reported Q4 earnings of $0.17 per share, missing the consensus estimate of $0.38, indicating a shortfall in profitability that may affect investor confidence.
- Sales Growth: Despite the earnings miss, Harrow's sales surged from $66.81 million to $89.09 million, exceeding the consensus of $88.45 million, reflecting strong market demand and operational performance.
- R&D Expenses: The company recorded $8.5 million in acquired in-process R&D expenses related to its acquisition of Melt Pharmaceuticals during Q4, which may drive future product development and market expansion.
- Future Outlook: Harrow expects fiscal 2026 sales between $350 million and $365 million, below the consensus estimate of $386.26 million, potentially raising concerns among investors regarding the company's growth trajectory.
See More
Harrow, Inc. Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: In Q4 2025, Harrow reported consolidated revenues of $89.1 million, reflecting a 33% year-over-year increase, with full-year revenues reaching $272 million, up 36% from 2024, indicating strong performance in the ophthalmic pharmaceuticals market.
- Strong EBITDA Performance: The adjusted EBITDA for Q4 was $24.2 million, with a full-year total of $61.9 million, representing a 54% year-over-year growth, showcasing the company's ongoing improvements in profitability and operational efficiency.
- Market Expansion Plans: Harrow plans to double the sales forces for VEVYE and TRIESENCE in 2026 and launch new products BYOOVIZ and BYQLOVI to further drive market penetration and revenue growth.
- Optimistic Future Outlook: Management expects full-year 2026 revenues to be between $350 million and $365 million, with adjusted EBITDA projected between $80 million and $100 million, reflecting confidence in future growth and strategic positioning.
See More
Surge in Options Trading Volume for GameStop and Harrow
- GameStop Options Volume: GameStop Corp saw options trading volume of 90,730 contracts, equivalent to approximately 9.1 million shares, representing about 124.2% of its average daily trading volume over the past month, indicating strong investor interest that could impact stock price volatility.
- High-Frequency Trading Insight: Notably, the $24 strike call option expiring on March 06, 2026, has seen 7,204 contracts traded today, representing approximately 720,400 underlying shares of GME, suggesting heightened market expectations for future price increases.
- Harrow Options Activity: Harrow Inc experienced options trading volume of 6,623 contracts, equivalent to about 662,300 shares, which is approximately 116.9% of its average daily trading volume over the past month, indicating increased activity and potential investor interest in the stock.
- Key Call Options: The $50 strike call option expiring on October 16, 2026, has recorded a trading volume of 1,060 contracts today, representing around 106,000 underlying shares of HROW, reflecting optimistic market sentiment regarding the stock's future performance.
See More
HROW Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: HROW's 52-week low is $20.85 per share, while the high is $54.85, with the last trade at $40.30, indicating significant price movement within this range and reflecting market interest and investor sentiment changes.
- Technical Indicator Observation: The current price of $40.30 is below the 52-week high, which may suggest a cautious market outlook on HROW's future performance, prompting investors to monitor whether it will break through the 200-day moving average for future trend indications.
- Market Sentiment Assessment: Despite significant fluctuations in HROW's stock price over the past year, the current price remains between the high and low points, indicating a divergence in market valuation that could influence investor decisions.
- Investor Focus: As HROW's stock price approaches the 52-week low, investors may reassess their strategies, particularly in light of increasing market volatility, necessitating close attention to relevant technical indicators and market dynamics.
See More
Harrow's Stock Drops 19% Following Lower-Than-Expected 2026 Revenue Forecast
- Company Performance: Harrow shares plummeted by 19% following disappointing revenue forecasts for 2026.
- Revenue Estimates: The company's projected revenue for 2026 fell below market expectations, contributing to the decline in share value.
See More
Harrow Inc. Reports Disappointing Earnings, Shares Decline
- Disappointing Earnings: Harrow Inc. reported fourth-quarter earnings of $0.17 per share, falling short of the consensus estimate of $0.38, indicating pressure on the company's profitability and potentially affecting investor confidence.
- Sales Growth: Despite the earnings miss, Harrow's sales surged from $66.81 million to $89.09 million, exceeding the consensus of $88.45 million, suggesting that the company still possesses growth potential in market demand.
- Increased R&D Expenses: The company recorded $8.5 million in acquired in-process research and development expenses related to the acquisition of Melt Pharmaceuticals during the fourth quarter and full year, which may impact short-term profits but lays the groundwork for future product line expansion.
- Cautious Future Outlook: Harrow expects fiscal 2026 sales between $350 million and $365 million, below the consensus estimate of $386.26 million, reflecting management's cautious stance on future performance, which could lead to further pressure on the stock price.
See More
Harrow Inc. Reports Mixed Q4 Results with Earnings Miss
- Earnings Performance: Harrow Inc. reported Q4 earnings of $0.17 per share, missing the consensus estimate of $0.38, indicating a shortfall in profitability that may affect investor confidence.
- Sales Growth: Despite the earnings miss, Harrow's sales surged from $66.81 million to $89.09 million, exceeding the consensus of $88.45 million, reflecting strong market demand and operational performance.
- R&D Expenses: The company recorded $8.5 million in acquired in-process R&D expenses related to its acquisition of Melt Pharmaceuticals during Q4, which may drive future product development and market expansion.
- Future Outlook: Harrow expects fiscal 2026 sales between $350 million and $365 million, below the consensus estimate of $386.26 million, potentially raising concerns among investors regarding the company's growth trajectory.
See More
Harrow, Inc. Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: In Q4 2025, Harrow reported consolidated revenues of $89.1 million, reflecting a 33% year-over-year increase, with full-year revenues reaching $272 million, up 36% from 2024, indicating strong performance in the ophthalmic pharmaceuticals market.
- Strong EBITDA Performance: The adjusted EBITDA for Q4 was $24.2 million, with a full-year total of $61.9 million, representing a 54% year-over-year growth, showcasing the company's ongoing improvements in profitability and operational efficiency.
- Market Expansion Plans: Harrow plans to double the sales forces for VEVYE and TRIESENCE in 2026 and launch new products BYOOVIZ and BYQLOVI to further drive market penetration and revenue growth.
- Optimistic Future Outlook: Management expects full-year 2026 revenues to be between $350 million and $365 million, with adjusted EBITDA projected between $80 million and $100 million, reflecting confidence in future growth and strategic positioning.
See More
Surge in Options Trading Volume for GameStop and Harrow
- GameStop Options Volume: GameStop Corp saw options trading volume of 90,730 contracts, equivalent to approximately 9.1 million shares, representing about 124.2% of its average daily trading volume over the past month, indicating strong investor interest that could impact stock price volatility.
- High-Frequency Trading Insight: Notably, the $24 strike call option expiring on March 06, 2026, has seen 7,204 contracts traded today, representing approximately 720,400 underlying shares of GME, suggesting heightened market expectations for future price increases.
- Harrow Options Activity: Harrow Inc experienced options trading volume of 6,623 contracts, equivalent to about 662,300 shares, which is approximately 116.9% of its average daily trading volume over the past month, indicating increased activity and potential investor interest in the stock.
- Key Call Options: The $50 strike call option expiring on October 16, 2026, has recorded a trading volume of 1,060 contracts today, representing around 106,000 underlying shares of HROW, reflecting optimistic market sentiment regarding the stock's future performance.
See More
HROW Stock 52-Week High and Low Analysis
- Price Fluctuation Analysis: HROW's 52-week low is $20.85 per share, while the high is $54.85, with the last trade at $40.30, indicating significant price movement within this range and reflecting market interest and investor sentiment changes.
- Technical Indicator Observation: The current price of $40.30 is below the 52-week high, which may suggest a cautious market outlook on HROW's future performance, prompting investors to monitor whether it will break through the 200-day moving average for future trend indications.
- Market Sentiment Assessment: Despite significant fluctuations in HROW's stock price over the past year, the current price remains between the high and low points, indicating a divergence in market valuation that could influence investor decisions.
- Investor Focus: As HROW's stock price approaches the 52-week low, investors may reassess their strategies, particularly in light of increasing market volatility, necessitating close attention to relevant technical indicators and market dynamics.
See More
Harrow's Stock Drops 19% Following Lower-Than-Expected 2026 Revenue Forecast
- Company Performance: Harrow shares plummeted by 19% following disappointing revenue forecasts for 2026.
- Revenue Estimates: The company's projected revenue for 2026 fell below market expectations, contributing to the decline in share value.
See More
Harrow Inc. Reports Disappointing Earnings, Shares Decline
- Disappointing Earnings: Harrow Inc. reported fourth-quarter earnings of $0.17 per share, falling short of the consensus estimate of $0.38, indicating pressure on the company's profitability and potentially affecting investor confidence.
- Sales Growth: Despite the earnings miss, Harrow's sales surged from $66.81 million to $89.09 million, exceeding the consensus of $88.45 million, suggesting that the company still possesses growth potential in market demand.
- Increased R&D Expenses: The company recorded $8.5 million in acquired in-process research and development expenses related to the acquisition of Melt Pharmaceuticals during the fourth quarter and full year, which may impact short-term profits but lays the groundwork for future product line expansion.
- Cautious Future Outlook: Harrow expects fiscal 2026 sales between $350 million and $365 million, below the consensus estimate of $386.26 million, reflecting management's cautious stance on future performance, which could lead to further pressure on the stock price.
See More
